
https://www.science.org/content/blog-post/young-blood-revisited
# Young Blood, Revisited (August 2015)

## 1. SUMMARY
This article updates the state of research into "young blood" - the phenomenon where infusing blood from younger animals into older ones appeared to reverse some aging effects. The piece highlights that human clinical trials were underway at the time from Alkahest, a Stanford startup. The trial was small (18 patients, ages 50-90 with mild to moderate Alzheimer's disease) and used a double-blind, crossover design where patients received either young human plasma or saline weekly for four weeks. The article notes a significant supply constraint: the world's plasma supply would only be sufficient to treat about 3% of the global Alzheimer's population, creating an immediate challenge if the therapy proved effective. Consequently, Alkahest and others were searching for the specific active components in plasma rather than relying on whole plasma transfusions.

## 2. HISTORY
Following the 2015 article, the research trajectory took several important turns. The initial excitement around young blood interventions led to continued clinical investigation, but the results have been mixed and largely disappointing.

**Clinical Trial Outcomes**: The early Alkahest trials did not demonstrate convincing clinical benefits. Larger and more rigorous studies failed to replicate the dramatic effects seen in animal models, particularly for Alzheimer's disease. While some small studies showed minor cognitive improvements, these were generally not statistically significant or clinically meaningful.

**Regulatory and Commercial Impact**: No plasma-based anti-aging or Alzheimer's treatments received FDA approval based on the young blood concept. The approach did not translate into approved therapies, and the initial commercial excitement around companies like Alkahest did not materialize into successful treatments reaching the market.

**Scientific Understanding**: Research did identify various factors in blood that change with age, including proteins, metabolites, and extracellular vesicles. However, the specific "fountain of youth" factors proved more complex than initially hoped. The field shifted toward understanding aging at a molecular level rather than pursuing direct plasma transfusions.

**Public and Ethical Concerns**: The concept attracted significant public interest and also raised ethical concerns about plasma donation, commercialization of blood products, and predatory marketing of unproven anti-aging therapies. Some questionable "young blood" clinics emerged, offering expensive treatments without scientific validation.

## 3. PREDICTIONS
• **Plasma supply constraints**: The article correctly predicted that supply would be a major issue, though this became moot since the treatment didn't demonstrate efficacy.

• **Search for active components**: This prediction was accurate - research did focus on identifying specific factors rather than using whole plasma, though this didn't lead to breakthrough therapies.

• **Immediate market transformation**: The article suggested young blood would "immediately become more valuable" - this didn't happen because the science didn't pan out clinically.

## 4. INTEREST
**Score: 4/9**

This article represents an interesting snapshot of legitimate scientific inquiry at a specific moment, but the research path ultimately led to negative results rather than therapeutic breakthroughs. While it captured genuine scientific investigation of an intriguing biological phenomenon, the long-term importance is limited by the failure to translate into clinical applications.


----
_model_params = {'model': 'nex-agi/deepseek-v3.1-nex-n1:free', 'input': '20150810-young-blood-revisited.txt', 'reasoning': {'effort': 'high'}, 'text': {'verbosity': 'medium'}, 'prompt-template': 'prompt-template-2'}_